

## List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/8187136/publications.pdf>

Version: 2024-02-01

156  
papers

5,669  
citations

57758

44  
h-index

85541

71  
g-index

163  
all docs

163  
docs citations

163  
times ranked

6032  
citing authors

#	ARTICLE	IF	CITATIONS
1	<sup>18</sup> F-FDG PET Uptake Characterization Through Texture Analysis: Investigating the Complementary Nature of Heterogeneity and Functional Tumor Volume in a Multi- <sup>18</sup> F Cancer Site Patient Cohort. <i>Journal of Nuclear Medicine</i> , 2015, 56, 38-44.	5.0	374
2	Correlation of high <sup>18</sup> F-FDG uptake to clinical, pathological and biological prognostic factors in breast cancer. <i>European Journal of Nuclear Medicine and Molecular Imaging</i> , 2011, 38, 426-435.	6.4	337
3	2009 EANM parathyroid guidelines. <i>European Journal of Nuclear Medicine and Molecular Imaging</i> , 2009, 36, 1201-1216.	6.4	272
4	Performance of FDG PET/CT in the Clinical Management of Breast Cancer. <i>Radiology</i> , 2013, 266, 388-405.	7.3	224
5	European Association of Nuclear Medicine Practice Guideline/Society of Nuclear Medicine and Molecular Imaging Procedure Standard 2019 for radionuclide imaging of pheochromocytoma and paraganglioma. <i>European Journal of Nuclear Medicine and Molecular Imaging</i> , 2019, 46, 2112-2137.	6.4	208
6	<sup>18</sup> F-FDG PET/CT for Staging and Restaging of Breast Cancer. <i>Journal of Nuclear Medicine</i> , 2016, 57, 175-265.	5.0	135
7	Prognostic Impact of <sup>18</sup> F-FDG-PET-CT Findings in Clinical Stage III and IIB Breast Cancer. <i>Journal of the National Cancer Institute</i> , 2012, 104, 1879-1887.	6.3	133
8	<sup>18</sup> F-FDG PET/CT bone/bone marrow findings in Hodgkin's lymphoma may circumvent the use of bone marrow trephine biopsy at diagnosis staging. <i>European Journal of Nuclear Medicine and Molecular Imaging</i> , 2010, 37, 1095-1105.	6.4	129
9	Molecular Imaging of Gastroenteropancreatic Neuroendocrine Tumors: Current Status and Future Directions. <i>Journal of Nuclear Medicine</i> , 2016, 57, 1949-1956.	5.0	119
10	The EANM practice guidelines for parathyroid imaging. <i>European Journal of Nuclear Medicine and Molecular Imaging</i> , 2021, 48, 2801-2822.	6.4	116
11	<sup>18</sup> F-FDG PET/CT in Staging Patients with Locally Advanced or Inflammatory Breast Cancer: Comparison to Conventional Staging. <i>Journal of Nuclear Medicine</i> , 2013, 54, 5-11.	5.0	114
12	The Yield of <sup>18</sup> F-FDG PET/CT in Patients with Clinical Stage IIA, IIB, or IIIA Breast Cancer: A Prospective Study. <i>Journal of Nuclear Medicine</i> , 2011, 52, 1526-1534.	5.0	99
13	Triple-Negative Breast Cancer: Early Assessment with <sup>18</sup> F-FDG PET/CT During Neoadjuvant Chemotherapy Identifies Patients Who Are Unlikely to Achieve a Pathologic Complete Response and Are at a High Risk of Early Relapse. <i>Journal of Nuclear Medicine</i> , 2012, 53, 249-254.	5.0	91
14	Dose Deposits from <sup>90</sup> Y, <sup>177</sup> Lu, <sup>111</sup> In, and <sup>161</sup> Tb in Micrometastases of Various Sizes: Implications for Radiopharmaceutical Therapy. <i>Journal of Nuclear Medicine</i> , 2016, 57, 759-764.	5.0	90
15	Functioning pulmonary metastases of thyroid cancer: does radioiodine influence the prognosis?. <i>European Journal of Nuclear Medicine and Molecular Imaging</i> , 2003, 30, 974-981.	6.4	85
16	Targeting Neuropeptide Receptors for Cancer Imaging and Therapy: Perspectives with Bombesin, Neurotensin, and Neuropeptide-Y Receptors. <i>Journal of Nuclear Medicine</i> , 2014, 55, 1650-1657.	5.0	85
17	Good clinical practice recommendations for the use of PET/CT in oncology. <i>European Journal of Nuclear Medicine and Molecular Imaging</i> , 2020, 47, 28-50.	6.4	85
18	Metastatic Renal Cell Carcinoma: Relationship Between Initial Metastasis Hypoxia, Change After 1 Month's Sunitinib, and Therapeutic Response: An <sup>18</sup> F-Fluoromisonidazole PET/CT Study. <i>Journal of Nuclear Medicine</i> , 2011, 52, 1048-1055.	5.0	82

#	ARTICLE	IF	CITATIONS
19	The Sentinel Node Procedure in Breast Cancer: Nuclear Medicine as the Starting Point. <i>Journal of Nuclear Medicine</i> , 2011, 52, 405-414.	5.0	82
20	Modern Nuclear Imaging for Paragangliomas: Beyond SPECT. <i>Journal of Nuclear Medicine</i> , 2012, 53, 264-274.	5.0	79
21	The Role of Radionuclide Imaging in the Surgical Management of Primary Hyperparathyroidism. <i>Journal of Nuclear Medicine</i> , 2015, 56, 737-744.	5.0	75
22	Comparison Between 18F-FDG PET Imageâ€‘Derived Indices for Early Prediction of Response to Neoadjuvant Chemotherapy in Breast Cancer. <i>Journal of Nuclear Medicine</i> , 2013, 54, 341-349.	5.0	74
23	Early Metabolic Response to Neoadjuvant Treatment: FDG PET/CT Criteria according to Breast Cancer Subtype. <i>Radiology</i> , 2015, 277, 358-371.	7.3	72
24	Preoperative imaging of parathyroid glands with technetium-99m-labelled sestamibi and iodine-123 subtraction scanning in secondary hyperparathyroidism. <i>Lancet, The</i> , 1999, 353, 2200-2204.	13.7	65
25	18F-FDG PET/CT Imaging for an Early Assessment of Response to Sunitinib in Metastatic Renal Carcinoma: Preliminary Study. <i>Cancer Biotherapy and Radiopharmaceuticals</i> , 2009, 24, 137-144.	1.0	65
26	Expression of Gastrin-Releasing Peptide Receptor in Breast Cancer and Its Association with Pathologic, Biologic, and Clinical Parameters: A Study of 1,432 Primary Tumors. <i>Journal of Nuclear Medicine</i> , 2017, 58, 1401-1407.	5.0	64
27	Do clinical, histological or immunohistochemical primary tumour characteristics translate into different 18F-FDG PET/CT volumetric and heterogeneity features in stage II/III breast cancer?. <i>European Journal of Nuclear Medicine and Molecular Imaging</i> , 2015, 42, 1682-1691.	6.4	63
28	Comparison between Three Promising Å–emitting Radionuclides, <sup>67</sup> Cu, <sup>47</sup> Sc and <sup>161</sup> Tb, with Emphasis on Doses Delivered to Minimal Residual Disease. <i>Theranostics</i> , 2016, 6, 1611-1618.	10.0	62
29	Comparative effectiveness of [ <sup>18</sup> F]â€‘fluorocholine PETâ€‘CT and pelvic MRI with diffusionâ€‘weighted imaging for staging in patients with highâ€‘risk prostate cancer. <i>Prostate</i> , 2015, 75, 323-331.	2.3	61
30	Bone metastases of differentiated thyroid cancer: impact of early 131I-based detection on outcome. <i>Endocrine-Related Cancer</i> , 2007, 14, 799-807.	3.1	60
31	Contribution of PET Imaging to the Diagnosis of Septic Embolism in Patients With Pacing Lead Endocarditis. <i>JACC: Cardiovascular Imaging</i> , 2016, 9, 283-290.	5.3	60
32	Performance of 18F-FDG PET/CT in the Characterization of Adrenal Masses in Noncancer Patients: A Prospective Study. <i>Journal of Clinical Endocrinology and Metabolism</i> , 2017, 102, 2465-2472.	3.6	59
33	18F-FDG PET/CT in the early prediction of pathological response in aggressive subtypes of breast cancer: review of the literature and recommendations for use in clinical trials. <i>European Journal of Nuclear Medicine and Molecular Imaging</i> , 2016, 43, 983-993.	6.4	58
34	CELLDOSE: A Monte Carlo Code to Assess Electron Dose Distributionâ€‘S Values for 131I in Spheres of Various Sizes. <i>Journal of Nuclear Medicine</i> , 2008, 49, 151-157.	5.0	53
35	Parathyroid Scintigraphy. <i>Clinical Nuclear Medicine</i> , 2012, 37, 568-574.	1.3	53
36	Early assessment with 18F-fluorodeoxyglucose positron emission tomography/computed tomography can help predict the outcome of neoadjuvant chemotherapy in triple negative breast cancer. <i>European Journal of Cancer</i> , 2014, 50, 1864-1871.	2.8	53

#	ARTICLE	IF	CITATIONS
37	Absorbed <sup>18</sup> F-FDG Dose to the Fetus During Early Pregnancy: FIGURE 1.. Journal of Nuclear Medicine, 2010, 51, 803-805.	5.0	52
38	High performances of <sup>18</sup> F-fluorodeoxyglucose PET-CT in cardiac implantable device infections: A study of 40 patients. Journal of Nuclear Cardiology, 2015, 22, 787-798.	2.1	50
39	[ <sup>123</sup> I]-FP-CIT and [ <sup>99m</sup> Tc]-HMPAO single photon emission computed tomography in a new sporadic case of rapid-onset dystonia "parkinsonism. Journal of the Neurological Sciences, 2008, 273, 148-151.	0.6	49
40	The NETPET Score: Combining FDG and Somatostatin Receptor Imaging for Optimal Management of Patients with Metastatic Well-Differentiated Neuroendocrine Tumors. Theranostics, 2017, 7, 1159-1163.	10.0	49
41	Baseline Tumor <sup>18</sup> F-FDG Uptake and Modifications After 2 Cycles of Neoadjuvant Chemotherapy Are Prognostic of Outcome in ER+/HER2 <sup>-</sup> Breast Cancer. Journal of Nuclear Medicine, 2015, 56, 824-831.	5.0	48
42	Infections in patients using ventricular-assist devices: Comparison of the diagnostic performance of <sup>18</sup> F-FDG PET/CT scan and leucocyte-labeled scintigraphy. Journal of Nuclear Cardiology, 2019, 26, 42-55.	2.1	48
43	Unilateral Surgery for Primary Hyperparathyroidism on the Basis of Technetium Tc 99m Sestamibi and Iodine 123 Subtraction Scanning. Archives of Surgery, 2000, 135, 1461.	2.2	47
44	Estrogen receptor <sup>+</sup> positive/human epidermal growth factor receptor 2 <sup>-</sup> negative breast tumors. Cancer, 2013, 119, 1960-1968.	4.1	47
45	Parathyroid Scintigraphy in Renal Hyperparathyroidism. Clinical Nuclear Medicine, 2013, 38, 630-635.	1.3	47
46	Evaluation of <sup>68</sup> Ga-DOTA-TOC PET/CT for the detection of duodenopancreatic neuroendocrine tumors in patients with MEN1. European Journal of Nuclear Medicine and Molecular Imaging, 2016, 43, 1258-1266.	6.4	47
47	STAT3 Mediates Nilotinib Response in KIT-Altered Melanoma: A Phase II Multicenter Trial of the French Skin Cancer Network. Journal of Investigative Dermatology, 2018, 138, 58-67.	0.7	47
48	<sup>18</sup> F-FDG PET/CT for the Early Evaluation of Response to Neoadjuvant Treatment in Triple-Negative Breast Cancer: Influence of the Chemotherapy Regimen. Journal of Nuclear Medicine, 2016, 57, 536-543.	5.0	40
49	Estimation of the <sup>125</sup> I Dose to the Embryo Resulting from <sup>18</sup> F-FDG Administration During Early Pregnancy: FIGURE 1.. Journal of Nuclear Medicine, 2008, 49, 679-682.	5.0	39
50	Radioactive iodine therapy, molecular imaging and serum biomarkers for differentiated thyroid cancer: 2017 guidelines of the French Societies of Nuclear Medicine, Endocrinology, Pathology, Biology, Endocrine Surgery and Head and Neck Surgery. Annales D'Endocrinologie, 2017, 78, 162-175.	1.4	39
51	Lymphoscintigraphy Can Select Breast Cancer Patients for Internal Mammary Chain Radiotherapy. International Journal of Radiation Oncology Biology Physics, 2012, 83, 1081-1088.	0.8	37
52	Hepatosplenic Candidiasis Imaged With F-18 FDG PET/CT. Clinical Nuclear Medicine, 2009, 34, 439-440.	1.3	34
53	Gallium-68: Chemistry and Radiolabeled Peptides Exploring Different Oncogenic Pathways. Cancer Biotherapy and Radiopharmaceuticals, 2013, 28, 85-97.	1.0	34
54	Parathyroid scintigraphy findings in chronic kidney disease patients with recurrent hyperparathyroidism. European Journal of Nuclear Medicine and Molecular Imaging, 2010, 37, 623-634.	6.4	31

#	ARTICLE	IF	CITATIONS
55	Variation of Liver SUV on 18FDG-PET/CT Studies in Women With Breast Cancer. <i>Clinical Nuclear Medicine</i> , 2013, 38, 422-425.	1.3	30
56	New Perspectives Offered by Nuclear Medicine for the Imaging and Therapy of Multiple Myeloma. <i>Theranostics</i> , 2016, 6, 287-290.	10.0	29
57	Novel insights into parathyroid hormone: report of The Parathyroid Day in Chronic Kidney Disease. <i>CKJ: Clinical Kidney Journal</i> , 2019, 12, 269-280.	2.9	29
58	Mapping the cellular distribution of labelled molecules by SIMS microscopy. <i>Biology of the Cell</i> , 1992, 74, 81-88.	2.0	28
59	Hypoxia Imaging of Uterine Cervix Carcinoma With 18F-FETNIM PET/CT. <i>Clinical Nuclear Medicine</i> , 2012, 37, 1065-1068.	1.3	27
60	Comparison of the binding of the gastrin-releasing peptide receptor (GRP-R) antagonist 68Ga-RM2 and 18F-FDG in breast cancer samples. <i>PLoS ONE</i> , 2019, 14, e0210905.	2.5	27
61	Radiation doses from 161Tb and 177Lu in single tumour cells and micrometastases. <i>EJNMMI Physics</i> , 2020, 7, 33.	2.7	27
62	Fatal Heart Failure After a 26-Month Combination of Tyrosine Kinase Inhibitors in a Papillary Thyroid Cancer. <i>Thyroid</i> , 2011, 21, 451-454.	4.5	24
63	New Fetal Dose Estimates from <sup>18</sup> F-FDG Administered During Pregnancy: Standardization of Dose Calculations and Estimations with Voxel-Based Anthropomorphic Phantoms. <i>Journal of Nuclear Medicine</i> , 2016, 57, 1760-1763.	5.0	24
64	Hodgkin lymphoma: a negative interim PET cannot circumvent the need for end-of-treatment PET evaluation. <i>British Journal of Haematology</i> , 2016, 175, 652-660.	2.5	23
65	Comparison of the radiolabeled PSMA-inhibitor 111In-PSMA-617 and the radiolabeled GRP-R antagonist 111In-RM2 in primary prostate cancer samples. <i>EJNMMI Research</i> , 2019, 9, 52.	2.5	23
66	18F-FDG-PET/CT in staging, restaging, and treatment response assessment of male breast cancer. <i>European Journal of Radiology</i> , 2014, 83, 1925-1933.	2.6	22
67	Bone Metastases of Differentiated Thyroid Cancer: The Importance of Early Diagnosis and 131I Therapy on Prognosis. <i>Journal of Nuclear Medicine</i> , 2008, 49, 1902-1903.	5.0	21
68	Tomoscintigraphy Improves the Determination of the Embryologic Origin of Parathyroid Adenomas, Especially in Apparently Inferior Glands: Imaging Features and Surgical Implications. <i>Journal of Nuclear Medicine Technology</i> , 2007, 35, 135-139.	0.8	20
69	Calculation of electron dose to target cells in a complex environment by Monte Carlo code <i>âœœCELLDOSEâœ</i> . <i>European Journal of Nuclear Medicine and Molecular Imaging</i> , 2009, 36, 130-136.	6.4	20
70	The evolving role of PET/CT in breast cancer. <i>Nuclear Medicine Communications</i> , 2010, 31, 271-273.	1.1	19
71	IN VIVO QUANTIFICATION OF 18F-FDG UPTAKE IN HUMAN PLACENTA DURING EARLY PREGNANCY. <i>Health Physics</i> , 2009, 97, 82-85.	0.5	18
72	Increased serum thyroglobulin levels and negative imaging in thyroid cancer patients. <i>Nuclear Medicine Communications</i> , 2010, 31, 1054-1058.	1.1	17

#	ARTICLE	IF	CITATIONS
73	Variability of Hepatic 18F-FDG Uptake at Interim PET in Patients With Hodgkin Lymphoma. <i>Clinical Nuclear Medicine</i> , 2015, 40, e405-e410.	1.3	17
74	Performing nuclear medicine examinations in pregnant women. <i>Physica Medica</i> , 2017, 43, 159-164.	0.7	16
75	Improved 18-FDG PET/CT diagnosis of multiple myeloma diffuse disease by radiomics analysis. <i>Nuclear Medicine Communications</i> , 2021, 42, 1135-1143.	1.1	16
76	Secondary ion mass spectrometry as a tool for investigating radiopharmaceutical distribution at the cellular level: the example of I-BZA and (14)C-I-BZA. <i>Journal of Nuclear Medicine</i> , 2005, 46, 1701-6.	5.0	16
77	Pulmonary Metastasis of Struma Ovarii. <i>Clinical Nuclear Medicine</i> , 2010, 35, 692-694.	1.3	15
78	18F-Fluorocholine PET/CT as a second line nuclear imaging technique before surgery for primary hyperparathyroidism. <i>European Journal of Nuclear Medicine and Molecular Imaging</i> , 2018, 45, 654-657.	6.4	15
79	Can we avoid inadvertent parathyroidectomy during thyroid surgery?. <i>In Vivo</i> , 2009, 23, 433-9.	1.3	15
80	Neurotensin Receptor-1 Expression in Human Prostate Cancer: A Pilot Study on Primary Tumors and Lymph Node Metastases. <i>International Journal of Molecular Sciences</i> , 2019, 20, 1721.	4.1	14
81	Lenvatinib plus Pembrolizumab for Renal Cell Carcinoma. <i>New England Journal of Medicine</i> , 2021, 385, 287-287.	27.0	14
82	SIMS microscopy: a tool to measure the intracellular concentration of carbon 14-labelled molecules. <i>Biology of the Cell</i> , 1992, 74, 89-92.	2.0	13
83	Prospective comparison of 18-FDG PET/CT and whole-body diffusion-weighted MRI in the assessment of multiple myeloma. <i>Annals of Hematology</i> , 2020, 99, 2869-2880.	1.8	13
84	Primary Hyperparathyroidism: Defining the Appropriate Preoperative Imaging Algorithm. <i>Journal of Nuclear Medicine</i> , 2021, 62, 3S-12S.	5.0	13
85	Should 'low-risk' thyroid cancer patients with residual thyroglobulin be re-treated with iodine 131?. <i>Clinical Endocrinology</i> , 2007, 66, 329-334.	2.4	12
86	Silicon-Containing Neurotensin Analogues as Radiopharmaceuticals for NTS1-Positive Tumors Imaging. <i>Bioconjugate Chemistry</i> , 2020, 31, 2339-2349.	3.6	12
87	Choline PET/CT in Multiple Myeloma. <i>Cancers</i> , 2020, 12, 1394.	3.7	12
88	On the effectiveness of recombinant human TSH as a stimulating agent for 131I treatment of metastatic differentiated thyroid cancer. <i>European Journal of Nuclear Medicine and Molecular Imaging</i> , 2010, 37, 2264-2266.	6.4	11
89	Design, synthesis, and biological evaluation of a multifunctional neuropeptide-Y conjugate for selective nuclear delivery of radiolanthanides. <i>EJNMMI Research</i> , 2020, 10, 16.	2.5	11
90	Scintigraphic Visualization of Glossal Thyroid Tissue During the Follow-up of Thyroid Cancer Patients. <i>Clinical Nuclear Medicine</i> , 2007, 32, 911-914.	1.3	10

#	ARTICLE	IF	CITATIONS
91	Stimulation test in the follow-up of thyroid cancer: Plasma rhTSH levels are dependent on body weight, not endogenously stimulated TSH values. <i>Nuclear Medicine Communications</i> , 2007, 28, 257-259.	1.1	10
92	Association of Radioactive Iodine Treatment of Hyperthyroidism With Cancer Mortality: An Unjustified Warning?. <i>Journal of Clinical Endocrinology and Metabolism</i> , 2020, 105, e1901-e1902.	3.6	10
93	Prognostic and predictive value of nuclear imaging in endocrine oncology. <i>Endocrine</i> , 2020, 67, 9-19.	2.3	9
94	Distant metastases of differentiated thyroid cancer: diagnosis, treatment and outcome. <i>Nuclear Medicine Review</i> , 2007, 10, 106-9.	0.5	9
95	Parathyroid gland radionuclide scanning methods and indications. <i>Joint Bone Spine</i> , 2002, 69, 28-36.	1.6	8
96	Pathological complete response in breast cancer. <i>Lancet, The</i> , 2015, 385, 114.	13.7	8
97	<sup>68</sup> Ga-PSMA-617 Compared With <sup>68</sup> Ga-RM2 and <sup>18</sup> F-FCholine PET/CT for the Initial Staging of High-Risk Prostate Cancer. <i>Clinical Nuclear Medicine</i> , 2019, 44, e535-e536.	1.3	8
98	Metastatic melanoma: can FDG-PET predict success of anti-PD-1 therapy and help determine when it can be discontinued?. <i>European Journal of Nuclear Medicine and Molecular Imaging</i> , 2020, 47, 2227-2232.	6.4	8
99	<sup>68</sup> Ga-Radiolabeling and Pharmacological Characterization of a Kit-Based Formulation of the Gastrin-Releasing Peptide Receptor (GRP-R) Antagonist RM2 for Convenient Preparation of [ <sup>68</sup> Ga]Ga-RM2. <i>Pharmaceutics</i> , 2021, 13, 1160.	4.5	8
100	A low thyroglobulin level cannot be used to avoid adjuvant <sup>131</sup> I therapy after thyroidectomy for thyroid carcinoma. <i>European Journal of Nuclear Medicine and Molecular Imaging</i> , 2009, 36, 169-171.	6.4	7
101	Advanced Hodgkin's lymphoma: End-of-treatment FDG-PET should be maintained. <i>European Journal of Nuclear Medicine and Molecular Imaging</i> , 2017, 44, 1254-1257.	6.4	7
102	What Is the Role of Dabrafenib Plus Trametinib Adjuvant Therapy in Stage IIIA Melanoma?. <i>Journal of Clinical Oncology</i> , 2019, 37, 1355-1356.	1.6	7
103	Slow Dynamic Lymphoscintigraphy Is Not a Reliable Predictor of Sentinel-Node Negativity in Cutaneous Melanoma. <i>Cancer Biotherapy and Radiopharmaceutics</i> , 2008, 23, 443-450.	1.0	6
104	Nuclear Medicine in Early-Stage Melanoma: Sentinel Node Biopsy FDG-PET/CT. <i>PET Clinics</i> , 2011, 6, 9-25.	3.0	6
105	Breast Cancer Patient With an Uncommon Lymphatic Drainage Evidenced by SPECT/CT. <i>Clinical Nuclear Medicine</i> , 2014, 39, e176-e179.	1.3	6
106	On the Role of Interim Fluorine- <sup>18</sup> -Labeled Fluorodeoxyglucose Positron Emission Tomography in Early-Stage Favorable Hodgkin Lymphoma. <i>Journal of Clinical Oncology</i> , 2017, 35, 2851-2852.	1.6	6
107	Risk of Hematologic Malignancies After Radioactive Iodine Treatment of Thyroid Cancer: An Unjustified Warning. <i>Journal of Clinical Oncology</i> , 2018, 36, 1881-1882.	1.6	6
108	Cryptorchidism as a potential source of misinterpretation in <sup>18</sup> F-FDG-PET imaging in restaging lymphoma patients. <i>Biomedicine and Pharmacotherapy</i> , 2013, 67, 533-538.	5.6	5

#	ARTICLE	IF	CITATIONS
109	Additional Diagnostic Value of Hybrid SPECT-CT Systems Imaging in Patients With Differentiated Thyroid Cancer. <i>American Journal of Clinical Oncology: Cancer Clinical Trials</i> , 2014, 37, 305-313.	1.3	5
110	Radioactive iodine ablation in low-risk thyroid cancer. <i>Lancet Diabetes and Endocrinology</i> , 2018, 6, 686.	11.4	5
111	Effect of variation in relaxation parameter value on LOR-RAMLA reconstruction of 18F-FDG PET studies. <i>Nuclear Medicine Communications</i> , 2009, 30, 926-933.	1.1	4
112	Prospective Comparison of 18-FDG PET/CT and Whole-Body MRI with Diffusion-Weighted Imaging in the Evaluation of Treatment Response of Multiple Myeloma Patients Eligible for Autologous Stem Cell Transplant. <i>Cancers</i> , 2021, 13, 1938.	3.7	4
113	Adjuvant therapy in stage IIIA melanoma. <i>Lancet Oncology</i> , 2021, 22, e299.	10.7	4
114	Accuracy of Positron Emission Tomography as a Diagnostic Tool for Lead Endocarditis: Design of the Prospective Multicentre ENDOTEP Study. <i>European Cardiology Review</i> , 2016, 11, 25.	2.2	4
115	Nivolumab with or without Relatlimab in Untreated Advanced Melanoma. <i>New England Journal of Medicine</i> , 2022, 386, 1860-1861.	27.0	4
116	La scintigraphie parathyroïdienne et ses indications actuelles. <i>Revue Du Rhumatisme (Edition) Tj ETQq0 0 0 rgBT /Overlock 10 Tf 50 46</i>	0.0	3
117	Plasma Exchanges Overcome Persistent Iodine Overload to Enable <sup>131</sup> I Ablation of Differentiated Thyroid Carcinoma. <i>Thyroid</i> , 2008, 18, 469-472.	4.5	3
118	Radiation Risk from Airport X-ray Backscatter Scanners: Should We Fear the Microsievert?. <i>Radiology</i> , 2011, 261, 330-331.	7.3	3
119	FDG PET/CT in Ovarian Cancer. <i>Clinical Nuclear Medicine</i> , 2012, 37, 54-56.	1.3	3
120	Variation de la captation hâ©patique de 18-FDG dans lâ©valuation intermâ©diaire des lymphomes B diffus Å grandes cellules en TEP/TDM. <i>Medecine Nucleaire</i> , 2014, 38, 83-90.	0.2	3
121	Internal Mammary Node Irradiation in Breast Cancer: The Issue of Patient Selection. <i>Journal of Clinical Oncology</i> , 2016, 34, 2673-2674.	1.6	3
122	Advantages and Limits of Targeted Radionuclide Therapy with Somatostatin Antagonists. <i>Journal of Nuclear Medicine</i> , 2018, 59, 546-547.	5.0	3
123	Prognostic utility of preâ©transplantation [ 18 F] fluorodeoxyglucose positron emission tomography/computed tomography in patients with diffuse large Bâ©cell lymphoma who underwent rituximab, dexamethasone, highâ©dose cytarabine, carboplatin salvage chemotherapy. <i>British Journal of Haematology</i> , 2020, 188, 268-271.	2.5	3
124	A Bright Future for Nuclear Endocrinology. <i>Journal of Nuclear Medicine</i> , 2021, 62, 1S-2S.	5.0	3
125	Parathyroid Imaging in Patients with Renal Hyperparathyroidism. , 2020, , 35-49.		3
126	Tc-99m Sestamibi and I-123 Detection of a Parathyroid Adenoma in the Presence of a Cold Thyroid Nodule. <i>Clinical Nuclear Medicine</i> , 1997, 22, 258-260.	1.3	3



#	ARTICLE	IF	CITATIONS
127	Prospective Comparison of 18F-Choline Positron Emission Tomography/Computed Tomography (PET/CT) and 18F-Fluorodeoxyglucose (FDG) PET/CT in the Initial Workup of Multiple Myeloma: Study Protocol of a Prospective Imaging Trial. <i>JMIR Research Protocols</i> , 2020, 9, e17850.	1.0	3
128	How to explain the sensitivity of DNA double-strand breaks yield to $125\text{I}$ position?. <i>International Journal of Radiation Biology</i> , 2023, 99, 103-108.	1.8	3
129	Backscatter x-ray machines at airports are safe. <i>Medical Physics</i> , 2012, 39, 4649-4652.	3.0	2
130	Somatostatin Antagonists for Radioligand Therapy of Nonendocrine Tumors. <i>Journal of Nuclear Medicine</i> , 2018, 59, 544-544.	5.0	2
131	Additional Evidence That End-of-Treatment Fluorodeoxyglucose-Positron Emission Tomography Evaluation Is Necessary in Advanced Hodgkin Lymphoma. <i>Journal of Clinical Oncology</i> , 2018, 36, 2124-2125.	1.6	2
132	Considerations on the Role of Pembrolizumab Adjuvant Therapy in AJCC-8 Stage IIIA Melanoma. <i>Journal of Clinical Oncology</i> , 2021, 39, 943-944.	1.6	2
133	Expression of neurotensin receptor-1 (NTS1) in primary breast tumors, cellular distribution, and association with clinical and biological factors. <i>Breast Cancer Research and Treatment</i> , 2021, 190, 403-413.	2.5	2
134	Lutetium-177 $\alpha$ -PSMA-617 for Prostate Cancer. <i>New England Journal of Medicine</i> , 2021, 385, 2494-2496.	27.0	2
135	Diagnostic Rechallenge with $^{18}\text{F}$ -FCH PET/CT Often Allows Minimally Invasive Parathyroidectomy While Maintaining Exceptional Cure Rates. <i>World Journal of Surgery</i> , 2022, 46, 2409-2415.	1.6	2
136	Patient Selection for Internal Mammary Node Irradiation: Lymphoscintigraphy Can Help. <i>Journal of Clinical Oncology</i> , 0, , .	1.6	2
137	Monte Carlo Simulation of Electron Dose from $^{131}\text{I}$ -Targeted Tumor Cells Within a Heterogeneous Tumor. <i>Cancer Biotherapy and Radiopharmaceuticals</i> , 2011, 26, 135-140.	1.0	1
138	Lognormal Distribution of Cellular Uptake of Radiopharmaceuticals: Implications for Biologic Response in Cancer Treatment. <i>Journal of Nuclear Medicine</i> , 2011, 52, 501-503.	5.0	1
139	Imaging Secondary Hyperparathyroidism. <i>American Journal of Roentgenology</i> , 2014, 203, W552-W552.	2.2	1
140	Re. <i>Clinical Nuclear Medicine</i> , 2017, 42, 576.	1.3	1
141	Interim [ $^{18}\text{F}$ ]Fluorodeoxyglucose-Positron Emission Tomography During Neoadjuvant Therapy in Human Epidermal Growth Factor Receptor 2-Positive Breast Cancer. <i>Journal of Clinical Oncology</i> , 2019, 37, 2091-2092.	1.6	1
142	Early use of abiraterone and radium-223 in metastatic prostate cancer. <i>Lancet Oncology</i> , The, 2019, 20, e229.	10.7	1
143	Diagnostic performance of imaging techniques for detecting of local recurrence after prostate brachytherapy. <i>Cancer Radiotherapie: Journal De La Societe Francaise De Radiotherapie Oncologique</i> , 2020, 24, 323-331.	1.4	1
144	Sentinel Node Biopsy in Patients With Thin Melanoma: A Need to Better Define the Aim. <i>Journal of Clinical Oncology</i> , 2020, 38, 3237-3238.	1.6	1

#	ARTICLE	IF	CITATIONS
145	Ribociclib plus Fulvestrant in Advanced Breast Cancer. <i>New England Journal of Medicine</i> , 2020, 382, e85.	27.0	1
146	<sup>18</sup> F-FDG-PET/CT Imaging in Breast Cancer Patients with Clinical Stage IIB or Higher. <i>Annals of Surgical Oncology</i> , 2020, 27, 1708-1709.	1.5	1
147	Optimising first-line treatment for metastatic renal cell carcinoma. <i>Lancet, The</i> , 2020, 395, e6.	13.7	1
148	Parathyroid Scintigraphy. , 2005, , .		1
149	Scintigraphie parathyroïdienne dans l'hyperparathyroïdie primitive: quelques considérations récentes. <i>Medecine Nucleaire</i> , 2014, 38, 208-215.	0.2	0
150	Putative Physiopathological Explanation for the "Sock Sign" in Bone Scans. <i>Clinical Nuclear Medicine</i> , 2016, 41, e420-e421.	1.3	0
151	Response to the letter by Adams and Kwee, entitled: "Unproven value of end-of-treatment FDG-PET in Hodgkin lymphoma". <i>European Journal of Nuclear Medicine and Molecular Imaging</i> , 2017, 44, 1937-1939.	6.4	0
152	Recommandations et référentiels. <i>Medecine Nucleaire</i> , 2019, 43, 1-4.	0.2	0
153	Thyroid cancer recurrence in the HiLo trial. <i>Lancet Diabetes and Endocrinology, the</i> , 2019, 7, 252.	11.4	0
154	PET-guided, BEACOPPescalated therapy in advanced Hodgkin lymphoma. <i>Lancet Oncology, The</i> , 2019, 20, e189.	10.7	0
155	Targeted radioactive therapy for prostate cancer. <i>Lancet, The</i> , 2021, 398, 487.	13.7	0
156	Predicting outcomes after <sup>177</sup> Lu-PSMA therapy in castration-resistant prostate cancer. <i>Lancet Oncology, The</i> , 2021, 22, e425.	10.7	0